Kimmtrak
What Kimmtrak is used for
Kimmtrak is indicated as monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Kimmtrak
- Active substance
- tebentafusp
- Disease area
- Uveal Neoplasms
- Medicine group
- Antineoplastic agents
- ATC code
- L01XX75
- Marketing authorisation holder
- Immunocore Ireland Limited
- Authorised in the EU since
- 2022
Official information
In the USA
Same active substance: Kimmtrak
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Kimmtrak used for?
Kimmtrak is indicated as monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
What is the active substance in Kimmtrak?
Kimmtrak contains tebentafusp.
Who makes Kimmtrak?
The EU marketing authorisation holder is Immunocore Ireland Limited.
Is Kimmtrak an orphan medicine?
Yes. Kimmtrak is designated an orphan medicine in the EU, for a rare disease (Uveal Neoplasms).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU